RB-522 Xenograft Model Service for Retinoblastoma

The RB-522 xenograft model represents a MYCN-amplified, RB1-wild-type retinoblastoma system that enables robust preclinical evaluation of novel therapeutics targeting aggressive intraocular malignancies. Alfa Cytology delivers customized, GLP-compliant RB-522 xenograft studies---including orthotopic intravitreal implantation, longitudinal tumor monitoring via bioluminescence imaging, and comprehensive histopathological endpoint analysis---to accelerate your retinoblastoma drug discovery pipeline from candidate selection to IND-enabling data packages.

Overview of RB-522 Xenograft Model for Retinoblastoma

Retinoblastoma is the most common primary intraocular malignancy in children, arising from the immature retina. While the majority of cases are driven by biallelic inactivation of the RB1 tumor suppressor gene, a rare but clinically significant subset is characterized by MYCN oncogene amplification with intact RB1 status. The RB-522 cell line belongs to this MYCN-amplified, RB1-wild-type subgroup, offering a distinct molecular landscape for preclinical investigation. In vivo, RB-522 cells form orthotopic xenografts upon intravitreal injection into immunodeficient hosts, recapitulating the intraocular growth pattern and aggressive proliferative behavior observed in high-risk retinoblastoma patients. The model has been validated in published efficacy studies comparing kinase inhibitor responses, demonstrating differential drug sensitivity profiles relative to RB1-deficient counterparts.

Orthotopic RB-522 xenografts are typically established in 3--4-week-old NOD-SCID or nude mice via intravitreal delivery of 25,000 cells/uL suspended in PBS with 10% Matrigel and 5% trypan blue. Tumor engraftment and progression can be monitored longitudinally through bioluminescence imaging following luciferase reporter transduction, or via tumor volume assessment on histological sections using human-specific mitochondrial markers. The RB-522 model is particularly valuable for evaluating agents targeting MYCN-driven oncogenic signaling, such as Aurora kinase inhibitors, where RB1 status dictates synthetic lethality and therapeutic window. This makes RB-522 an essential comparator line in preclinical portfolios aiming to stratify retinoblastoma subtypes and develop precision oncology approaches.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting MYCN-driven retinoblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving retinoblastoma progression in RB1-wild-type contexts, and how treatments intersect with MYCN amplification-driven oncogenic signaling.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for RB1-status stratification.

Figure 1. Soft agar colony formation analysis in retinoblastoma cell lines. (Ryl, Tatsiana, et al., 2024)

Cell Line Information: RB-522

The RB-522 cell line is a well-characterized human retinoblastoma line derived from tumor material extracted from an enucleated eye of a retinoblastoma patient. It represents the MYCN-amplified, RB1-wild-type molecular subtype, distinguishing it from the more common RB1-mutant retinoblastomas. Comprehensive genomic and molecular profiling has established its authentication and relevance as a preclinical model.

Our Services

Alfa Cytology provides end-to-end RB-522 xenograft model services tailored to your preclinical retinoblastoma program. From orthotopic tumor establishment and longitudinal in vivo imaging to comprehensive histopathological and molecular endpoint analysis, our experienced scientific team ensures reproducible, high-quality data packages that meet IND-enabling standards. Whether you require single-agent efficacy studies, combination therapy screening, or pharmacokinetic-pharmacodynamic correlation, we design each study protocol to align with your compound's mechanism of action and developmental stage.

Workflow of RB-522 Xenograft Model Construction

The construction of the RB-522 orthotopic xenograft model follows a standardized, reproducible workflow optimized for intraocular tumor engraftment and longitudinal therapeutic assessment. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Preparation and Quality Control: RB-522 cells are expanded from authenticated low-passage cryogenic stocks and verified for viability (>95%), mycoplasma negativity, and STR identity confirmation prior to injection.
2. Cell Suspension Formulation: Cells are harvested, washed, and resuspended at 25,000 cells/uL in sterile PBS containing 10% Matrigel (BD Bioscience) and 5% trypan blue for visualization during injection.
3. Animal Preparation and Anesthesia: 3--4-week-old NOD-SCID or nude mice are acclimatized and anesthetized under isoflurane inhalation; pupils are dilated pharmacologically to optimize surgical access to the vitreous cavity.
4. Intravitreal Injection: Using a Hamilton micro-syringe, 2 uL of the RB-522 cell suspension is delivered into the right vitreous cavity under stereomicroscopic guidance; the uninjected left eye serves as internal control.
5. Tumor Engraftment Monitoring: Tumor establishment is confirmed by bioluminescence imaging (for luciferase-transduced lines) or ophthalmic examination; engraftment typically occurs within 7--14 days post-injection.
6. Treatment Administration: Test compounds are administered via intravitreal injection, systemic routes, or local delivery according to study design, with dosing initiated once tumors reach predetermined baseline radiance or volume thresholds.
7. Longitudinal Assessment: Tumor burden is quantified serially through bioluminescence flux (photons/second) or caliper-based volume estimation; body weight and clinical signs are recorded to monitor tolerability.
8. Endpoint Analysis and Sample Collection: At study termination, eyes are enucleated and processed for histopathology (H&E, IHC with human mitochondrial marker MAB1273), tumor volume morphometry, and molecular profiling of residual disease.

Figure 2: Schematic workflow illustrating the derivation and construction of the RB-522 Xenograft Model at Alfa Cytology.

Case Study-RB-522 Xenograft Model Development

Alfa Cytology has successfully developed and validated the RB-522 orthotopic xenograft platform for multiple retinoblastoma therapeutic programs. In a representative engagement, RB-522 tumors were established in NOD-SCID mice with consistent engraftment rates and dose-dependent responses to reference compounds. Longitudinal bioluminescence imaging captured tumor growth kinetics, while terminal histopathology confirmed intraocular tumor architecture and human-specific marker retention. Detailed efficacy data, including tumor growth inhibition rates, survival curves, and pharmacodynamic biomarker modulation, are available under confidentiality agreements. Clients interested in accessing specific case study datasets---including compound-class benchmarking and combination regimen outcomes---are invited to contact our business development team for a customized data presentation.

Why Choose Alfa Cytology?

Alfa Cytology combines deep oncology model expertise with rigorous operational standards to deliver retinoblastoma xenograft data you can trust. Our RB-522 service is built on authenticated cell stocks, validated orthotopic protocols, and integrated endpoint capabilities that streamline your preclinical decision-making.

• Verified Cell Line Integrity: Authenticated RB-522 cell stocks with confirmed MYCN amplification and RB1-wild-type status, backed by STR profiling and low-passage banking.
• High Take Rates and Consistency: Proven orthotopic intravitreal injection expertise in NOD-SCID and nude mouse strains, ensuring consistent tumor take rates and reproducible growth kinetics.
• Integrated Imaging Capabilities: Integrated longitudinal imaging platform (bioluminescence, OCT-compatible) enabling real-time tumor burden quantification without serial sacrifice.
• Comprehensive Analytical Support: Comprehensive histopathology suite including human-specific mitochondrial IHC (MAB1273), H&E morphometry, and retinal layer invasion scoring.
• Tailored Study Designs: Flexible study designs accommodating single-agent efficacy, combination therapy, dose-response, and pharmacokinetic-pharmacodynamic correlation objectives.
• GLP-Compliant Data Packages: GLP-compliant data packages and audited report generation suitable for IND submission and regulatory briefing documents.
• Dedicated Project Management: Dedicated project management with PhD-level scientific oversight ensuring protocol customization, interim data review, and rapid milestone communication.

Contact Us

Ready to advance your retinoblastoma therapeutic program with the RB-522 xenograft model? Contact us today to discuss your study objectives, receive a customized proposal, and access our confidential case study portfolio. Our team is prepared to design a preclinical strategy that aligns with your target product profile and accelerates your path to IND. Please reach out to us today via our inquiry form or email to learn more about our RB-522 Xenograft Model services.

For research use only. Not intended for any clinical use.